Cenobamate safe and effective in children, study finds

12 Apr 2022

The new epilepsy medicine, cenobamate, has been found to be safe and effective in children with hard-to-treat focal-onset epilepsy, in line with study findings in adults with epilepsy. This is according to a piece of research from the US by Dr Robin Varughese and colleagues, published in the journal Epilepsy & Behavior.

The team set out to assess how safe and effective cenobamate is as an add-on treatment in children with hard-to-treat focal-onset seizures. They said this medicine is useful in adults but this has not yet been confirmed for children.

The study included 21 children, aged around 16 years old, on average. Cenobamate was introduced and the dose slowly increased as needed or up to a maximum of 400mg a day. On average, children weighing over 50kg needed around 200mg a day. In children weighing under 50kg, the average dose was 4mg a day for each kilo they weighed. The average reduction in seizure frequency was over half. Around three in five children (62.5%) had their seizures reduce by at least half. In over half of the children, seizures reduced by three-quarters, similar to the seizure reduction in adults. Just under one in five children (19%) became seizure free.

Of the 21 children, nine (42.8%) had side effects from cenobamate, which were usually problems with their balance or speech (ataxia) in about a quarter (23.8%) or sleepiness (sedation) in about one in 10 (9.5%). Three children dropped out of the study because of the side effects.

The researchers concluded that their findings show that cenobamate has similar effectiveness and safety in children as it does in adults, making it effective, safe and well-tolerated even at the maximum doses a day. However, larger studies are needed to confirm their results.

At the moment, cenobamate is only approved for use in adults. Doctors can only prescribe it for children on an unlicensed (off-label) basis. This means the doctor has to take individual responsibility for prescribing it. They will only do so if they are satisfied there is enough evidence it’s safe and effective, and that there are no approved medicines that would work instead.  

The full study is available online.

 

You may also be interested in...

Epilepsy medicine cenobamate recommended for use on the NHS

The National Institute for health and Care Excellence (NICE) has recommended the use of cenobamate for treating focal onset seizure in adults with hard-to-treat epilepsy on the NHS.

There are no comments yet. Be the first to comment...

Question about your epilepsy?

Your question will be sent to our helpline advisors.

Have a comment about this page?

All comments are reviewed by a moderator before publishing. Comments will be edited or deleted if they are offensive, libellous, slanderous, abusive, commercial or irrelevant.

We ask for your email when you make a comment through this website. This means that we can let you know directly that we have replied to you. By making a comment through the website, you allow us to use the comment in our publicity without using your name. If we would like to use your name, we will email you to get your permission.

The content of this field is kept private and will not be shown publicly.
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
14 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.